Background: A new formulation of a botulinum neurotoxin type A (BoNTA-ABO; Dysport [abobotulinumtoxinA], Medicis Aesthetics, Scottsdale, AZ) has recently been approved in the United States for the treatment of moderate to severe glabellar lines. Objective: We describe the results of four phase III studies of BoNTA-ABO for the treatment of glabellar lines. Methods: Of the four studies reported here, three were double-blind, multicenter, randomized, placebo-controlled studies and one was an open-label extension study. A second phase III, open-label extension study is ongoing. Studies enrolled ethnically diverse, healthy adults with glabellar lines of at least moderate severity at maximum frown. Patients were followed for up to 180 days after treatment. The fixed-dose, single treatment study randomized 158 patients to receive placebo or a single 50-unit BoNTA-ABO dose. The fixed-dose, repeat treatment study enrolled 311 patients to assess treatment following repeat BoNTA-ABO treatment of 50 units. A variable-dose study randomized 816 patients to receive placebo or a single variable dose (50 to 80 units, based on gender and muscle mass assessment). The fourth phase III study was open-label to evaluate repeat dosing (50 units). Clinical evaluations were performed on days 14 and 30, and monthly thereafter. Primary efficacy endpoints were based on the investigators' and patients' assessment of glabellar line severity at day 30 using wrinkle severity rating scales. Responders were defined as patients who had a composite 2ϩ grade improvement in wrinkle severity, meaning that a patient had a baseline Glabellar Line Severity Scale (GLSS) score of 2 (moderate glabellar lines) and a day 30 GLSS score of 0 (no glabellar lines/none), or a baseline GLSS score of 3 (severe glabellar lines) and a day 30 GLSS score of 0 (no glabellar lines/none) or 1 (mild glabellar lines), for both the blinded investigator's and patient's assessments. Results: Patients (1116 total; 720 BoNTA-ABO, 396 placebo) treated with BoNTA-ABO received 50 to 80 units. The median duration of response was 85 days for fixed dosing and 109 days for variable dosing. Similar efficacy occurred at doses adjusted for gender and muscle mass, although male patients required higher doses than female patients in the variable-dose study. Responses appeared as early as 24 hours, with a median time to onset of three days. The open-label extension study evaluated 1200 patients for 13 months. Maintenance of efficacy was seen after multiple treatment cycles, indicating that patients did not develop a tolerance. A second open-label study is ongoing and is not included in this report. Conclusions: BoNTA-ABO significantly improved moderate to severe glabellar lines compared with placebo, with onset of effect seen as soon as 24 hours after treatment and a median duration of effect of 85 and 109 days for fixed and variable dosing, respectively. (Aesthet Surg J; 
Treatment with botulinum neurotoxin type A (BoNT-A) suppresses muscular activity in the glabellar area and leads to inhibition of the formation of glabellar lines caused by muscle activity during facial expression. 15 Expression-related generation of glabellar lines is apparent at maximum frown and BoNT-A may not be expected to completely relieve glabellar lines noted at rest. Therefore, clinical studies focus on the correction of glabellar lines appearing at maximum frown. Nevertheless, lines appearing when the patient's face is at rest are also evaluated because some glabellar lines caused by increased resting tone in glabellar muscles may be relieved with BoNT-A treatment.
We report the combined efficacy results of four phase III studies conducted to evaluate BoNTA-ABO for the treatment of glabellar lines. [16] [17] [18] [19] A fifth phase III study is being conducted 20 and the results of this ongoing safety study are not included in this report. The individual study designs are summarized here and individual study results have been previously reported. [16] [17] [18] [19] [20] The combined efficacy was analyzed across studies for specific doses. These results are presented for the BoNTA-ABO 50-unit fixed dose, the variable dose (50 to 80 units), and repeat administrations of BoNTA-ABO 50 units. Subset populations were also analyzed and are reported across studies.
METHODS
Three of the four phase III trials [16] [17] [18] were designed as multicenter, double-blind, placebo-controlled, randomized trials. The fourth phase III study 19 was open-label. All studies enrolled ethnically diverse healthy adults (18 years of age or older) with glabellar lines of at least moderate severity at maximum frown. Patients were excluded if they had eyelid or brow ptosis, deep dermal scarring, or a substantial inability to lessen glabellar lines by physically spreading them apart. The majority of participants were never exposed to botulinum toxin before the time of study recruitment.
All clinical investigations were conducted according to the principles of the Declaration of Helsinki and approval was obtained from the appropriate institutional review board before initiation of the study. A signed informed consent form was provided by each patient.
Patients received either placebo or a total dose of 50 to 80 units of BoNTA-ABO administered in five injection sites in a V-shaped pattern in the glabellar region ( Figure  1) . A single-use sterile 300-unit vial of BoNTA-ABO was reconstituted with 2.5 mL or 1.5 mL of 0.9% sodium chloride injection USP without preservative. The total dose was delivered in equally divided aliquots to five specified injection sites in the glabellar region (0.04 to 0.07 mL per injection point) on day zero. Follow-up visits occurred on days 14, 30, and monthly thereafter up to 180 days. Patients completed a diary card on days one through seven to record the onset of treatment effect.
The Brandt et al study, the first of three double-blind studies, was a fixed-dose single treatment study of 158 botulinum toxin-naïve patients randomized to receive either placebo or 50 units of BoNTA-ABO. 16 The Rubin et al study was a fixed-dose retreatment study of BoNTA-ABO administered to 311 botulinum toxin-naïve patients. Patients initially received either one or two open-label treatments (cycles A1 and A2) with 50 units of BoNTA-ABO for up to 270 days. 17 Patients who had returned to a glabellar line severity score (GLSS) of moderate or severe were then randomized 2:1, BoNTA-ABO (50 units) to placebo, for retreatment (cycle B). Upon return to a GLSS of moderate or severe, BoNTA-ABO treated patients from cycle B were rerandomized to either placebo or BoNTA-ABO 50 units (cycle C). Cycle C was used to evaluate efficacy in order to assess response after multiple cycles of BoNTA-ABO treatment. Study participation lasted for a maximum of 23 months and patients received up to four treatments. The third double-blind, randomized study, by Kane et al, 18 was a variable-dose study that randomized 816 patients to receive a single BoNTA-ABO treatment or placebo, with dose based on gender and muscle mass (50, 60, or 70 units in women and 60, 70, or 80 units in men). 18 This study also included patients of African ethnicity and Fitzpatrick skin types IV, V, or VI. 21 The fourth phase III study, by Moy et al, 19 was an open-label extension study to evaluate the long-term use of BoNTA-ABO (50 units) after repeat treatments. Another open-label, phase III extension study 20 is ongoing and interim safety results have been reported. Data from the Monheit et al study 20 are not included in this report. The four phase III studies discussed in this report are listed in Table 1 .
The severity of glabellar lines was assessed based on an investigator's or blinded evaluator's live assessments using a validated four-point photographic scale (0 = no glabellar lines, 1 = mild, 2 = moderate, and 3 = severe; Table 2 ). Patients evaluated the appearance of their glabellar lines using a static four-point categorical scale (Table 3) . For Brandt et al, 16 as a secondary global assessment, patients also evaluated the appearance of their glabellar lines using a nine-point scale (Table 4 ). Investigators' and patients' assessments occurred at days zero, 14, 30, and monthly, up to day 150 in Kane et al 18 and to day 180 in Brandt et al. 16 Assessments for Rubin et al 17 occurred at days zero, 14, and 30 (cycle C).
The primary endpoint for the integrated analysis of efficacy was a composite 2+ grade improvement from baseline at day 30. Although the studies were not designed to capture this endpoint, it was requested by the US Food and Drug Administration (FDA). A composite 2+ grade improvement was defined as a patient who had a baseline GLSS of moderate wrinkles/moderate (grade = 2) and a day 30 GLSS of no wrinkles/none (grade = 0), or a baseline GLSS of severe wrinkles/severe (grade = 3) and a day 30 GLSS of no wrinkles/none (grade = 0) or mild wrinkles/mild (grade = 1), for both the blinded evaluator's/blinded investigator's and patient's assessments (Table 5) .
Secondary efficacy endpoints were the composite 1+ grade improvement, defined as a patient who had a baseline GLSS of moderate wrinkles/moderate (grade = 2) or severe wrinkles/severe (grade = 3) and a day 30 GLSS of no wrinkles/none (grade = 0) or mild wrinkles/mild (grade = 1) for both the blinded evaluator's/investigator's and patient's assessments.
RESULTS
Efficacy results are based on data from Brandt et al, 16 cycle C of Rubin et al 17 (up to study day 30), and Kane 19 were used to show the extended efficacy of BoNTA-ABO.
The three controlled studies [16] [17] [18] in the integrated analysis included 1116 patients (720 treated with BoNTA-ABO, 396 treated with placebo). Patients received 50 to 80 units of BoNTA-ABO. A total of 1080 patients (701 BoNTA-ABO, 379 placebo) completed the course of treatment.
Demographic data were similar among the doubleblinded studies (Table 6 ). Patients ranged in age from 19 to 80 years. Demographics for patients receiving 50 units from Brandt et al, 16 cycle C of Rubin et al, 17 and Kane et al 18 (the 50-unit subset) were analyzed together. The mean age for the population treated with the 50 unit dose was approximately 44 years, and the majority of patients were female (87% in both treatment groups) and white (placebo 67%; BoNTA-ABO 63%). Most patients (96%) were naïve to botulinum toxin at the time they were recruited. The baseline GLSS was similar between patients treated with placebo and BoNTA-ABO (placebo 44% moderate, 56% severe; BoNTA-ABO 47% moderate, 53% severe).
In the Kane et al 18 variable-dose study the mean ages were similar for patients who received placebo and BoNTA-ABO (49.2 and 48.7 years, respectively). In both treatment groups, patients were mostly female (88%) and white (70% and 67% for placebo and BoNTA-ABO, respectively). This study also enrolled 150 ethnically African patients with Fitzpatrick skin types IV, V, and VI, of which 54 patients received placebo and 106 patients received BoNTA-ABO. Also meeting these Fitzpatrick criteria were patients of an ethnicity other than African. Most patients (approximately 80%) in both treatment groups were naïve to botulinum toxin exposure.
BoNTA-ABO efficacy was significantly superior to that of placebo (P < .001) at both the 50-unit dose and the variable dose, according to the applicable efficacy criteria. In individual studies, the minimum response rate by different variables was always more than 50% for BoNTA-ABO, in contrast to a range of 0% to 9% for placebo.
The composite 2+ grade improvement for the 50-unit dose at maximum frown at day 30 with BoNTA-ABO was 57% (111/196; P < .001), compared to 0% with placebo (Table 7) . Similarly, in the variable-dose study, the composite 2+ grade improvement for patients treated with BoNTA-ABO was 59% (319/538), compared with less than 1% (1/267) for placebo.
A composite 1+ grade improvement was recorded in 76.5% (150/196) of patients receiving BoNTA-ABO, compared with 1% (1/133; P < .001) of patients receiving placebo (Table 8) . Investigators reported the same improvement in 89% (174/196) of patients receiving BoNTA-ABO, compared with 6% (8/133; P < .001) of patients receiving placebo. A 1+ grade improvement was reported in 79% (155/196) of patients receiving BoNTA-ABO, compared to 5% (7/133; P < .001) of patients receiving placebo, according to patients' assessments.
Moreover, at every point in time, there was a statistically significant greater proportion of responders in the BoNTA-ABO group compared with the placebo group through day 150 (P = .037) by the investigator's assessment (91%, 89%, 72%, 50%, 28%, and 14% for days 14, 30, 60, 90, 120, and 150, respectively) and by patients' self-evaluation through day 120 (P = .009; 84%, 79%, 67%, 44%, 22%, and 11% for days 14, 30, 60, 90, 120, and 150, respectively; Table 9 ). 
Subset Populations
Age. In all age groups except the age category of 65 years and older, BoNTA-ABO was effective compared with placebo and there was no overlap of the confidence intervals (CI) among treatment groups. The sample size for the age category of 65 years and older (six patients receiving placebo and five patients receiving BoNTA-ABO) was too small for valid analysis.
Gender. Male patients received higher doses than female patients in the variable-dose Kane et al study. 18 Facial muscle mass was graded separately for male and female patients as +, ++, or +++. The majority of male patients (65%) were categorized in the heavy/large (+++) muscle mass group; of those male patients categorized with a heavy/large muscle mass, 90% had severe glabellar lines. For female patients, the majority (59%) were categorized in the moderate/medium (++) muscle mass group; of these, 45% had moderate glabellar lines and 55% had severe glabellar lines. Male patients received a total volume of 0.5 mL to 0.7 mL (60, 70, or 80 units) of BoNTA-ABO divided equally among five injection points. Female patients received 0.4 mL to 0.6 mL (50, 60, or 70 units) of BoNTA-ABO divided equally among five injection points.
When both male and female patients received the 50-unit fixed dose, response rates for composite 1+ and 2+ grade improvements were lower for male BoNTA-ABO, abobotulinumtoxinA; SD, standard deviation. *Includes patients indicating "Other" as their race/ethnicity. † Investigator's live assessment of glabellar lines at maximum frown. ‡ Fitzpatrick skin type: I-extremely fair, always burns, never tans; II-white, always burns, sometimes tans; III-white, sometimes burns, always tans; IV-olive or light brown, rarely burns, always tans; V-brown, never burns; and VI-heavily pigmented or black, never burns. Percentages are based on the total number of patients in each treatment group. For the 50-unit dose, data from Brandt et al, 16 cycle C of Rubin et al, 17 and Kane et al 18 (50-unit subset placebo and BoNTA-ABO) are included. Variable-dose data are from study Kane et al. 18 patients (35% and 23%, respectively) than for female patients (83% and 62%, respectively). However, when doses were adjusted for gender and muscle mass, nearly similar efficacy was observed between males and females. The responder rate in male patients was higher in the variable dose population than in the 50-unit dose population, increasing from 23% to 46% in composite 2+ grade improvement and from 35% to 59% in composite 1+ grade improvement. For female patients, who had smaller muscle mass overall, the response rates were similar for the 50-unit dose and the variable dose.
Race and Ethnicity: Hispanic and African Patients
The nonwhite demographic subgroup from Brandt et al 16 and Kane et al 18 included a large number of Hispanic patients. Kane et al 18 was specifically designed to enroll 150 or more patients of African ethnicity. Based on the enrollment numbers, analyses were conducted to examine the comparability of the Hispanic and African populations with the entire population. The comparison was conducted with 50-unit dose patients for the Hispanic population from Brandt et al 16 BoNTA-ABO, abobotulinumtoxinA; CI, confidence interval. *Comparison between treatment groups performed using the Mantel-Haenszel chi-square test stratified by study. †Comparison between treatment groups performed using the Mantel-Haenszel chi-square test stratified by race (white, African, and any other race) and pooled center. The denominator for the proportions is the number of patients in each treatment group with nonmissing data at the specified visit and a rating of "moderate" (2) or "severe" (3) on the baseline assessment. For the 50-unit dose, data from Brandt et al, 16 cycle C of Rubin et al, 17 BoNTA-ABO, abobotulinumtoxinA. *Comparison between treatment groups were performed using the Mantel-Haenszel chi-square test stratified by study. The denominator for the proportions is the number of patients in each treatment group with nonmissing data at the specified visit and a rating of "moderate" (2) or "severe" (3) on the baseline assessments. Data from Brandt et al 16 , cycle C of Rubin et al, 17 and Kane et al 18 (50-unit subset placebo and BoNTA-ABO) are included. † Data for two patients were missing at the time of data cutoff for both the placebo arm and the BoNTA-ABO arm. BoNTA-ABO, abobotulinumtoxinA. *Percent (responders/number of patients with nonmissing data).
Hispanic patients responded better than white patients to BoNTA-ABO treatment, as evidenced by the fact that there was no overlap in CI. There were no responders in the placebo groups. The composite 2+ response rate for all patients treated with BoNTA-ABO in the 50-unit population from the three controlled phase III studies was 57% (111/196; 95% CI 0.494-0.637). For Hispanic patients from Brandt et al, 16 the response rate for patients treated with BoNTA-ABO was 79% (38/48; 95% CI 0.650-0.895).
In contrast, Hispanic and African patients treated with BoNTA-ABO in the variable-dose Kane et al study 18 demonstrated comparable composite 2+ response rates. Overlapping CIs confirmed that the differences were not significant. The 2+ response rate for Hispanic patients treated with BoNTA-ABO was 75% (43/57; 95% CI 0.622-0.859) and it was 68% for African patients treated with BoNTA-ABO (71/105; 95% CI 0.578-0.764). These response rates were comparable to those seen in the total population, 59% (319/538; 95% CI 0.550-0.635).
Onset of Response
Onset of response to treatment was defined as the first diary day that a patient responded "Yes" to the question "Since being injected, have you noticed any effect on the appearance of your glabellar lines (lines between your eyebrows)?", or a GLSS score of 0 (none) or 1 (mild) using the blinded evaluator's/blinded investigator's live assessment at maximum frown, or a score of "No wrinkles" (0) or "Mild wrinkles" (1) using the patient's assessment at maximum frown at day 14.
The onset of efficacy for the BoNTA-ABO group was seen as soon as 24 hours. The median time to onset was three to four days, with a range of one to 20 days. In the BoNTA-ABO treatment group, at least 75% of patients responded by day six or seven.
For the 50-unit dose group, the onset of response was calculated from patient diary data or from day 14 visit data from Brandt et al, 16 cycle C of Rubin et al, 17 and Kane et al 18 (50-unit subset; Table 10 ). Overall, a significant (P < .001) percentage of patients responded to treatment (93% for BoNTA-ABO versus 29% for placebo). Results from the variable-dose Kane et al study 18 also showed an onset of effect for BoNTA-ABO treatment as early as 24 hours (Table 10 ). The overall percentage of patients who responded to treatment was 94% for BoNTA-ABO versus 11% for placebo, a statistically significant difference (P < .001).
Gender differences were apparent in the time to onset. Male patients treated with BoNTA-ABO had a median time to onset of response of three days for the 80-unit subset and four days for the 60-and 70-unit subsets, based on patients' diary cards or assessments at day 14.
Duration of Response
The median duration of treatment response was defined as the number of days before a responder reexhibited a GLSS score of moderate (grade = 2) or severe (grade = 3) following onset of treatment response. The duration of treatment response to BoNTA-ABO was evaluated in Brandt et al 16 and Kane et al. 18 The duration of treatment response was extended from 85 days (by investigators' and patients' assessments) at the 50-unit dose to 107 days (by patients' assessments) and 109 days (by blinded evaluators' live assessment) when dosing was based on muscle mass and gender. Throughout the observation period, the Kaplan-Meier estimates of the probability of a patient being a responder was 85% starting at 14 days for patients receiving BoNTA-ABO treatment and 8% for patients receiving placebo in the same period. The majority of patients treated with BoNTA-ABO (61%) had continued response at 90 days, compared with 3% of those who received placebo. BoNTA-ABO, abobotulinumtoxinA; CI, confidence interval. *Onset of response to treatment is defined as the first diary day a patient responded "Yes" to the question "Since being injected, have you noticed any effect on the appearance of your glabellar lines (lines between your eyebrows)?", or a score of "none" (0) or "mild" (1) using blinded evaluator's/blinded investigator's assessment at maximum frown, or a score of "no wrinkles" (0) or "mild wrinkles" (1) using patient's assessment at maximum frown at day 14. † Wilcoxon test for treatment difference. For the 50-unit dose, the Wilcoxon test is stratified by study (Brandt et al, 16 Kane et al, 18 Rubin et al 17 rerandomization). For the variable dose, the Wilcoxon test is stratified by pooled center and race (white, African, and other race). For the 50-unit dose, data from Brandt et al, 16 cycle C of Rubin et al, 17 and Kane et al 18 (50-unit subset placebo and BoNTA-ABO) are included. 19 the overall median duration was approximately 88 days by investigators' assessment and 84 days by patients' assessment, and it did not decrease with repeat administrations of BoNTA-ABO. These results support the conclusion reached in Rubin et al. 17 The proportion of responders was comparable across all cycles and by both investigators' and patients' assessments, revealing a maintenance of efficacy with no evidence of tachyphylaxis (Table 11) . Tolerance, as measured by the presence or absence of tachyphylaxis and of serum anti-Clostridium toxin antibodies, is reported elsewhere in this supplement.
DISCUSSION
Four studies evaluated BoNTA-ABO for the treatment of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients. The three placebo-controlled studies showed significant (P < .001) efficacy versus placebo both individually and by the integrated analysis of composite 2+ grade improvement. The open-label extension study, together with data from Rubin et al, 17 provides evidence that patients did not develop a tolerance to BoNTA-ABO after repeated administrations.
Onset of response was seen as early as one day postinjection and the response lasted as long as 109 days. A minimum dose of 50 units of BoNTA-ABO is recommended to achieve a clinical effect. Doses of up to 70 units for adult female patients and 80 units for adult male patients were administered based on a clinical assessment of muscle mass (ie, small, medium, or large).
The placebo-controlled fixed-dose phase III studies by Brandt et al 16 and Rubin et al 17 confirmed the efficacy and safety of BoNTA-ABO (50 units). The variable-dose study by Kane et al 18 reflected the current standard clinical practice to adjust the dose of botulinum toxin to meet the individual patient's needs based on muscle mass. The open-label Moy et al study 19 confirmed the feasibility of repeat dosing with BoNTA-ABO without loss of efficacy.
Greater muscle mass may have a higher threshold of response, causing male patients to be less responsive than female patients at the doses used. At the 50-unit dose, female patients had a greater proportion of responders in the BoNTA-ABO group by investigators' and patients' assessments (93% and 83%, respectively) as compared with male responders (67% and 33%, respectively). However, when doses were adjusted for muscle mass in Kane et al, 18 the percentage of male patients who responded increased. Response rates for female patients in this study were equivalent to those seen in the fixed dose study. Comparable efficacy was seen in patients under the age of 65 and in all racial groups.
BoNTA-ABO was approved by the FDA in April 2009 for the treatment of glabellar lines. This formulation has been used successfully for many years in Europe and other countries under the tradename Dysport (Clostridium botulinum type A hemagglutinin complex; Ipsen Biopharm, Wrexham UK) for therapeutic indications such as dystonia, spasticity, and for cosmetic indications. 1 In the United States, the proposed dose of BoNTA-ABO (50 units) for the treatment of glabellar lines is a relatively small dose when compared with doses used for therapeutic or medical indications of the drug. Because the location, size, and use of the muscles vary markedly among individuals of both genders, variable dosing customized to individual musculature and gender may provide greater efficacy and a longer duration of effect on glabellar lines.
CONCLUSIONS
BoNTA-ABO significantly improved moderate to severe glabellar lines when compared with placebo. Onset of effect was seen as soon as 24 hours after treatment 19 at day 30 across all cycles using investigators' live assessment and patients' selfassessment of glabellar lines at maximum frown and the median duration of effect was 85 or 109 days, for fixed or variable dosing, respectively. The new formulation of BoNT-A is another option for physicians to offer their patients seeking treatment of their glabellar lines in pursuit of a more youthful appearance.
